Novel antibiotics: Are we still in the pre–post-antibiotic era?

Infection

Volumn 43, Issue 2, 2015, Pages 145-151

  Draenert, R ^a   Seybold, U ^a   Grutzner E ^a   Bogner, J R ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Avibactam; Cadazolid; Ceftolozane; Omadacycline; Tedizolid

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTIONS; BACTERIUM; DRUG EFFECTS; HUMAN; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS;

EID: 84939974943     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-015-0749-y     Document Type: Review

References (51)

1. Dalhoff A. Resistance surveillance studies: a multifaceted problem—the fluoroquinolone example. Infection. 2012;40:239–62.
2. Lubbert C, et al. Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case–control analysis. Infection. 2014;42:309–16.
3. Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clin Infect Dis. 2012;54:S214–9.
4. Rubino CM, et al. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother. 2009;53:4422–8.
5. Belley A, et al. Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother. 2013;57:205–11.
6. Dunbar LM, et al. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother. 2011;55:3476–84.
7. Corey GR, Jiang H, Moeck G. Dalbavancin or oritavancin for skin infections. N Engl J Med. 2014;371:1162–3.
8. Seltzer E, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis. 2003;37:1298–303.
9. Jauregui LE, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41:1407–15.
10. Raad I, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis. 2005;40:374–80.
11. Nord CE, Rasmanis G, Wahlund E. Effect of dalbavancin on the normal intestinal microflora. J Antimicrob Chemother. 2006;58:627–31.
12. Dorr MB, et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother. 2005;55:ii25–30.
13. Boucher HW, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370:2169–79.
14. Flanagan S, Passarell J, Lu Q. Tedizolid population pharmacokinetics, exposure–response, and target attainment. Antimicrob Agents Chemother. 2014;58:6462–70.
15. Liapikou A, et al. New antimicrobial approaches to gram positive respiratory infections. Pulm Pharmacol Ther. 2014 (Epub ahead of print).
16. Moran GJ, et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014;14:696–705.
17. Rybak JM, Marx K, Martin CA. Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance. Pharmacotherapy. 2014;34:1198–208.
18. Flanagan S, et al. Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid. Pharmacotherapy. 2014;34:891–900.
19. Flanagan S, Minassian SL, Morris D. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment. Antimicrob Agents Chemother. 2014;58:6471–6.
20. Beringer P, et al. Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings. Antimicrob Agents Chemother. 2005;49:3676–81.
21. Shorr AF, et al. Analysis of the phase 3 ESTABLISH trials: tedizolid versus linezolid in acute bacterial skin and skin structure infection. Antimicrob Agents Chemother. 2015;59:864–71.
22. Flamm RK, et al. Ceftazidime–avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). Diagn Microb Infect Dis. 2014;80:233–8.
23. Higgins PG, et al. In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii. J Antimicrob Chemother. 2012;67:1167–9.
24. Mima T, et al. In vitro activity of BAL30072 against Burkholderia pseudomallei. Int J Antimicrob Agents. 2011;38:157–9.
25. Mushtaq S, et al. Activity of BAL30072 alone or combined with beta-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters. J Antimicrob Chemother. 2013;68:1601–8.
26. OnVista. GNW-News: Basilea beginnt Phase-1-Kombinationsstudie mit ihrem gramnegativen Antibiotikum BAL30072 und Meropenem. 2014 05.10.2104. http://www.onvista.de/news/gnw-news-basilea-beginnt-phase-1-kombinationsstudie-mit-ihrem-gramnegativen-antibiotikum-bal30072-und-meropenem-1007603.
27. OnVista. Präsentation umfangreicher Daten zu Basileas Anti-Infektiva Isavuconazol, Ceftobiprol und BAL30072 auf ICAAC. http://www.onvista.de/news/praesentation-umfangreicher-daten-zu-basileas-anti-infektiva-isavuconazol-ceftobiprol-und-bal30072-auf-icaac-1127929.
28. Farrell DJ, et al. Antimicrobial activity of ceftolozane–tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011–2012). Antimicrob Agents Chemother. 2013;57:6305–10.
29. Farrell DJ, et al. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents. 2014;43:533–9.
30. Sader HS, et al. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12). J Antimicrob Chemother. 2014;69:2713–22.
31. Personal communication of CUBIST Pharmaceuticals, December 17th 2014.
32. FDA. FDA approves new antibacterial drug Zerbaxa. 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427534.htm.
33. Lucasti C, et al. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane–tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014;58:5350–7.
34. Maseda E, et al. Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections. Expert Rev Anti Infect Ther. 2014;12:1–15.
35. Bretonniere C, et al. In vivo efficacy of ceftolozane against Pseudomonas aeruginosa in a rabbit experimental model of pneumonia: comparison with ceftazidime, piperacillin/tazobactam and imipenem. Int J Antimicrob Agents. 2014;44:218–21.
36. Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55:649–58.
37. Siala W, et al. Antibiotic activity against biofilms from Staphylococcus aureus clinical isolates: factors determining the activity of the investigational fluoroquinolone delafloxacin in comparison with daptomycin and vancomycin. Antimicrob Agents Chemother. 2014;58:6385–97.
38. National_Institutes_of_Health_USA. Registry of publicly and privately supported clinical trials. 2014 05.10.2014. https://clinicaltrials.gov.
39. Oldach D, et al. Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. Antimicrob Agents Chemother. 2013;57:2526–34.
40. Van Bambeke F. Renaissance of antibiotics against difficult infections: focus on oritavancin and new ketolides and quinolones. Ann Med. 2014;46:512–29.
41. Sader HS, Flamm RK, Jones RN. Antimicrobial activity of ceftaroline–avibactam tested against clinical isolates collected from U.S. Medical Centers in 2010–2011. Antimicrob Agents Chemother. 2013;57:1982–8.
42. Livermore DM, et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2011;55:390–4.
43. Actavis. Actavis announces positive topline results from the phase III program of ceftazidime–avibactam in patients with complicated intra-abdominal infections (cIAI) 2014 05.10.2014. http://www.actavis.com/news/news/thomson-reuters/actavis-announces-positive-topline-results-from-th.
44. Hirsch EB, et al. In vitro activity of MK-7655, a novel beta-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 2012;56:3753–7.
45. Griffith DC, et al. A phase 1 study of the safety, tolerability, and pharmacokinetics of the beta-lactamase inhibitor RPX7009 in health adult subjects, in 24th European congress of clinical microbiology an infectious diseases ECCMID 20142014: Barcelona.
46. Nordmann P, et al. Characterisation of beta-lactamase inhibition by AAI101, an extended-spectrum beta-lactamase inhibitor, in 24th European congress of clinical microbiology an infectious diseases ECCMID 20142014: Barcelona.
47. Locher HH, et al. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother. 2014;58:892–900.
48. Chilton CH, et al. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. J Antimicrob Chemother. 2014;69:697–705.
49. Baldoni D, et al. Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses. J Antimicrob Chemother. 2014;69:706–14.
50. Louie T, et al. Multicentre, double-blind, randomised, phase 2 study evaluating the novel antibiotic, cadazolid, in subjects with Clostridium difficile-associated diarrhoea. Abstract LB 2956, 22nd European congress of clinical microbiology and infectious disease, Berlin, April 27–30, 2013.
51. Wall Street Journal. Actelions neuartiges Antibiotikum Cadazolid erhält Einstufung als Qualified Infectious Disease Product (QIDP-Status) zur Behandlung von Clostridium-difficile-assoziierter Diarrhoe durch die FDA 2014 05.10.2104. http://www.wallstreet-online.de/nachricht/6606569-actelions-neuartiges-antibiotikum-cadazolid-einstufung-qualified-infectious-disease-product-qidp-status-behandlung-clostridium-difficile-assoziierter-diarrhoe-fda.